← Eichor
Study identifier: NCT05363657 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors

Condition: Kidney Cancer  ·  Sponsor: Azienda Ospedaliero-Universitaria Careggi

PhaseN/A
Planned participants10000
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Partial nephrectomy (PN) is the standard treatment for localized renal masses and should be preferred in clinical T1 (\<7 cm tumor diameter) renal tumors over radical nephrectomy (RN) whenever technically feasible. Nonetheless, indications, approaches, techniques for PN, and correct reporting of outcomes, are still a matter of great debate within the urology community. Concurrently, case-report series suggested that alternative strategies for the treatment of localized renal tumors (ablation techniques (AT), watchful waiting (WW), active surveillance (AS)) could be feasible with acceptable oncologic outcomes in particular settings of patients with localized renal tumors. In this complex clinical scenario, the role surgeon-related and environmental factors (such as surgical experience, hospital resources, countries' social background and performance of health system) are important to address the best personalized approach in patients with renal tumors. In the light of current evidence, many unsolved questions still remain and many unmet needs must be addressed. In particular, 1) the risk-benefit trade-offs between PN and RN for anatomically complex renal localized tumors; 2) the definition of evidence-based strategies to tailor the management strategy (AT vs WW vs AS vs surgery) in different subset of patients with particular clinical conditions (i.e. old, frail, comorbid patients); and 3) the definition of evidence-based recommendations to adapt surgical approach (open vs la…

This description comes directly from the study's public registry record.

Talk to the study team

Marco Carini, Prof.  ·  055 794 6351  ·  carini@unifi.it

Andrea Minervini, Prof.  ·  055 794 6351  ·  andrea.minervini@unifi.it

Always discuss trial participation with your own doctor first.

Locations (37)

Institute of Urology, University of Southern California.Los Angeles, California, United StatesRecruiting
University of California San Diego, Moores Cancer CenterSan Diego, California, United StatesRecruiting
Stanford UniversityStanford, California, United StatesNot Yet Recruiting
Loyola University Medical Center, Edward Hines VA HospitalChicago, Illinois, United StatesNot Yet Recruiting
University of PennsylvaniaPhiladelphia, Pennsylvania, United StatesNot Yet Recruiting
VCU Health SystemRichmond, Virginia, United StatesRecruiting
Swedish HospitalSeattle, Washington, United StatesNot Yet Recruiting
Medical University of Vienna, Vienna General HospitalVienna, AustriaRecruiting
University of BruxellesBrussels, BelgiumRecruiting
University Hospitals LeuvenLeuven, BelgiumNot Yet Recruiting
Onze Lieve Vrouw HospitalLeuven, BelgiumRecruiting
Santa Casa da Misericórdia de FortalezaFortaleza, BrazilRecruiting

+ 25 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05363657